{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-036925","form_type":"8-K","ticker":"PTIX","cik":"0001022899","company_name":"Protagenic Therapeutics, Inc.new","filed_at":"2024-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.918453+00:00","generated_at":"2026-05-31T03:50:23.419375+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protagenic Therapeutics updates PT00114 milestones: Phase I multi-dose Q4 2024, Phase IIa Q3 2025","bullets":["Multiple dose portion of Phase I study for PT00114 expected to commence Q4 2024.","Results from multiple dose portion of Phase I study for PT00114 expected Q2 2025.","Initiation of Phase IIa study for PT00114 expected Q3 2025.","Company will provide further updates to clinical development schedule as it becomes clearer."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-036925","json":"https://secwatch.observer/filing/0001493152-24-036925.json","markdown":"https://secwatch.observer/filing/0001493152-24-036925.md","text":"https://secwatch.observer/filing/0001493152-24-036925.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022899/000149315224036925/0001493152-24-036925-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022899/000149315224036925/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T03:50:23.419375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}